No abstract available.
Glomerulonephritis, IGA ; Glycosaminoglycans ; Immunoglobulin A

No abstract available.
Glomerulonephritis, IGA ; Glycosaminoglycans ; Immunoglobulin A

Fructose 1,6-bisphosphate aldolase (FPA) was recently known as new member of heparin binding proteins and a new method for FPA purification has been proposed (Thanh Van Ta et all, J. Biochem. 125, 554-559,199) by measuring FPA - heparin binding inhibition caused by various glycosaminoglycans (GAGs), affinity of the two isoforms, aldolase A4 and C4, to the GAGs underphysiological ionic conditions was estimated. Among glycosaminoglycans employd, heparin was confirmed to be the unique one that could bind specifically these enzymes. In the lower ionic strength, the affinity order of both FPA isoforms (A4 and C4) to these GAGs appeared as heparin> chondroitin polysulfate> heparin sulfate > dermatan > chondrointin sulfate A > chondroin sulfate C. Employing the same techniques, the affinity of regioselectively desulfated heparins to FPA was estimated. Our results indicated that, among the sulfate groups is heparin, loss of N-sulfate group reduced most significantly the affinity to FPA A4 and C4. This sugests that FPA recognizes a specific heparin structure including the sulfo-amino group at C2 of the glucosamine residue as the vital factor in this interaction.
Fructose-Bisphosphate Aldolase ; Glycosaminoglycans

Palmar digital vein thrombosis causing one or more nodules seems to be a relatively rare condition. Only 20 cases of palmar digital vein thrombosis have been reported worldwide in the English language literature. It presents with a painful, firm and blue nodule located at or in close proximity to one of the flexion creases. The etiology remains unknown, but changes in the vessel wall related to the anatomic characteristics of the palmar digital veins may play a role, along with intraluminal stasis. Two patients with blue nodule located in close proximity to flexion creases on the volar side of the finger presented to our hospital. Histological examination showed organizing thrombus within the dilated vessel. We report here on these two cases of palmar digital vein thrombosis.
Fingers ; Glycosaminoglycans ; Humans ; Thrombosis ; Veins

Pericardial cysts are reported by some authors, but epicardial cysts are extremely rare. We report one case of epicardial cyst that was detected incidentally and was removed successfully. Furthermore, unusually, pathological examinations confirmed that the cyst wall was looked like a vessel wall.
Glycosaminoglycans ; Heart Ventricles ; Mediastinal Cyst

An aneurysm is a focal, localized dilatation of a blood vessel. This term is most commonly applied to dilatation of arteries. However, dilatation can occur in any part of the vascular system. Primary true aneurysm of the superficial venous system that contains all the vascular layers is known to be very rare. We report here on surgically treating a case of primary true aneurysm on the dorsalis pedis vein and we briefly review the related literature.
Aneurysm ; Arteries ; Blood Vessels ; Dilatation ; Glycosaminoglycans ; Veins

A persistent sciatic artery (PSA) is very rare congenital vascular anomaly which is present in 0.025% to 0.04% of the population by an angiographic study. A PSA is usually combined with aneurismal disease or thromboembolic events because of its arteriosclerosis and vessel wall degeneration. The treatments of symptomatic PSA are comprised of exclusion of PSA from circulation and bypass surgery for the lower limb. However, surgical treatment should be tailored to its anatomy and presentation. We report a successful treatment of PSA with distal thromboembolism by thromboembolectomy without bypass surgery.
Arteries ; Arteriosclerosis ; Glycosaminoglycans ; Lower Extremity ; Thromboembolism

We presented a case that an acute in-stent thrombosis after the deployment of a Wingspan stent was successfully managed with a stent in-stent technique. Because vessel perforation and subarachnoid hemorrhage were iatrogenically developed during the procedure, we were unable to use the thrombolytic agents to correct the in-stent thrombosis. When a thrombotic complication following an intracranial stent placement occurs with a coincidentally hemorrhagic complication, the stent in-stent technique should be considered as a treatment option.
Fibrinolytic Agents ; Glycosaminoglycans ; Stents ; Subarachnoid Hemorrhage ; Thrombosis

PURPOSE: To clinically establish the effectiveness and safety of bevacizumab on recurrent pterygium. METHODS: Twenty patients with recurrent pterygium were given a subconjunctival injection of 0.3 cc bevacizumab, and were evaluated for periodic clinical results at 1 week, 2 weeks, 4 weeks, and every month thereafter. The patients were also evaluated for clinical results and complications. RESULTS: Of recurrent pterygium patients with bevacizumab injection, the conjunctival injection decreased maximally after 1 to 2 weeks, but significantly increased at 4 weeks (above the lowest level measured at 1 to 2 weeks), and no patient presented conjunctival injection above the pre-injection level at 3 months, except in 2 cases. Two weeks after the injection, ICG anterior segment angiography revealed a significant decrease (30.14+17.69%) in vessel thickness of the pterygium 2 weeks after the bevacizumab injection compared to before the injection. There had been no cases of progression of pterygium, and no ocular or systemic complications due to bevacizumab. CONCLUSIONS: As shown above in the results, subconjunctival injection of 0.3 cc bevacizumab decreased the conjunctival injection and effectively suppressed any further progression of pterygium. Thus, bevacizumab subconjunctival injection appears to be effective in recurrent pterygium treatment instead of surgical methods.
Angiography ; Antibodies, Monoclonal, Humanized ; Glycosaminoglycans ; Humans ; Pterygium ; Bevacizumab

Mucopolysaccharidosis (MPS) and mucolipidosis(ML) belong to a group of rare genetic disorders of lysosomal enzymes and share some clinical manifestations. MPS is characterized by the accumulation of glycosaminoglycans (GAG) and results from the impaired function of one of 11 enzymes required for normal GAG degradation. ML, which is clinically similar to several forms of MPS, is caused by deficiency of Nacetylglucosamine-1-phosphotransferase activity. Therapeutic strategies for MPS, including enzyme replacement therapy and bone marrow transplantation, have been developed with some success. In this review, we discuss clinical feature, diagnostic methods, management and the present status of research on MPS and ML.
Bone Marrow Transplantation ; Enzyme Replacement Therapy ; Glycosaminoglycans ; Mucolipidoses* ; Mucopolysaccharidoses*